Drug updated on 7/25/2024
| Dosage Form | Injection (intravenous; 2 g/vial [1 g meropenem (equivalent to 1.14 g meropenem trihydrate) and 1 g vaborbactam]) |
| Drug Class | Antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.
Latest News
Summary
- Meropenem and vaborbactam (Vabomere) is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including pyelonephritis caused by designated susceptible bacteria.
- Information was derived from two systematic reviews/meta-analyses focusing on Vabomere's safety and effectiveness in treating cUTIs.
- In one study, novel antibiotics like Vabomere showed higher clinical cure rates at test of cure (TOC) compared to conventional antibiotics, with a comparable safety profile regarding adverse events.
- Another study found that while Vabomere had higher clinical and microbiological treatment success rates against carbapenem-resistant uropathogens compared to other carbapenems, it also presented a higher risk of adverse events.
- Both studies focused on adult patients aged 18 years or older with cUTIs; however, specific subpopulation data were not detailed in these studies.
- Overall, Vabomere demonstrated significant efficacy but posed a relatively higher risk of adverse events when used as first-choice treatment for carbapenem-resistant cUTI.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vabomere (meropenem and vaborbactam) Prescribing Information. | 2023 | Melinta Therapeutics, LLC., Lincolnshire, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: a systematic review and meta-analysis of randomized controlled trials. | 2023 | International Journal of Antimicrobial Agents |
| Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection. | 2020 | Medicine Open |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. | 2023 | Infectious Disease Society of America |
| Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). | 2021 | Clinical Infectious Diseases |